<DOC>
<DOCNO> CNN19981221.1130.1007 </DOCNO>
<DOCTYPE> NEWS </DOCTYPE>
<TXTTYPE> CAPTION </TXTTYPE>
<TEXT>
A biotech giant wins the rights to sell a blockbuster drug. I'm John 
defterios in New York with this edition of "Dollars & Sense." In a 
surprising legal victory amgen has won a battle over rival Johnson 
and johnson. The decision gives amgen rights to mesp the successor 
the epo a popular drug and a top selling product for both. A panel 
dismissed the claim that the drug was covered by a 13-year-old licensing 
agreement between the two companies. The victory could boost amgen's 
share of the $3 billion global market for such drugs. 
</TEXT>
</DOC>